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ABSTRACT 
Nifedipine has been shown to be an effective and a well 
tolerated medication for the treatment of several cardiova-
scular diseases. Its low water solubility, however, leads to 
poor drug absorption from oral dosage forms while commercia-
lly available soft capsules lead to a short half - life. 
In this study a method was developed to prepare contro-
l led release nifedipine tablets which would release the drug 
quickly and sustain the release for a longer period of time. 
Solid dispersions of nifedipine with polyvinylpyrrolidone 
(40T) and polyethylene glycol 8000 were prepared to enhance 
dissolution and microporous polypropylene containing 75% 
void space was used to control the release to a desired 
level. 
Various ratios of the two polymers were used. The 
results indicate that the solid dispersion technique is a 
good approach to enhance the dissolution of nifedipine. 
However the polypropylene polymer used as a homogeneously 
dispersed matrix does not provide a zero - order release 
rate in low concentrations. 
A preliminary study was also carried out to measure the 
rate of photodegradation of nifedipine solution in a normal-
ly lighted lab devoid of sunlight. The results obtained show 
that the photodegradation of nifedipine follows first order 
kinetics with a t 90 of 19 minutes. The pH of the solution in 
the range of 4 .2 - 7 .4 did not alter this rate. 
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The solubility of nifedipine in water was found to be 
about 5 mg/L at 25 degrees Celcius. There was no significant 
difference between the water solubility and the solubility 
in phosphate buffer (pH 7.4) or the solubility in 0.1 N HCl. 
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"For the things we 
have to learn before 
we can do them, we 
learn by doing them" 
- Aristotle 
iv 
( 
ACKNOWLEDGEMENTS 
I would like to express my sincerest gratitude to my 
advisor, Dr. Joan M. Lausier for her interest, support and 
guidance throughout this project. 
I would also like to thank the members of my committee, 
Dr. Stanley Barnett, Dr. Anthony Paruta, Dr. Christopher 
Rhodes, and Dr. Chen for their time and effort in evalua-
ting this thesis. 
The suggestions and assistance I have received from the 
faculty members, graduate students and post doctoral fellows 
of the college of pharmacy is greatly appreciated. In parti-
cular I am indebted to Dr. H. Zia and to Dr. Ramesh (Medici-
nal Chemistry) for their constructive criticism and assis-
tance during several stages of this project. 
Finally I would like to extend my thanks to Dr. Mahen-
dra Dedhiya and Miles Pharmaceuticals, Conn., for providing 
generous samples of nifedipine and to Enka Indusrial Pro-
ducts Inc., Illinois., for providing samples of Accurel. 
v 
TABLE OF CONTENTS 
( 
Abstract 
Acknowledgements 
List of Tables 
List of Figures 
I. Introduction 
II. Purpose of this study 
III. Experimental 
IV. Results and discussion 
v. Conclusions 
VI. Bibliography 
( 
( 
vi 
LIST OF TABLES 
( 
Page 
I.Composition of controlled release tablets of 
nifedipine ......................................... 40 
II. Resolution obtained from the various 
mobile phase systems ............................... 45 
III. Photodegradation of nifedipine ..................... 52 
IV. Solubility of nifedipine and its copreci-
pitate at 25 degrees ............•.................. 55 
V. Physical characteristics of tablets ................ 57 
VI. Dissolution of Adalat capsules ..................... 59 
VII. Dissolution of nif edipine powder . .................. 60 
VIII. Dissolution of tablets Tl and T2 under 
non - sink conditions . ............................. 61 ( 
IX. Dissolution of tablets T3 and T4 under 
non - sink conditions . ............................. 62 
x. Comparison of UV and HPLC assay results 
for dissolution of tablet T 1 ....................... 66 
XI. Comparison of UV and HPLC assay results 
for dissolution of tablet T2 •••.••••••••••.•..•..•• 67 
XII. Comparison of UV and HPLC assay results 
for dissolution of tablet T3 ....................... 68 
XIII. Comparison of UV and HPLC assay results 
for dissolution of tablet T4 ..•.•..••••............ 69 
XIV. Dissolution of tablets Tl, T2 and T4 in 
"near - sink" conditions ........................... 70 
( 
vii 
Page 
( 
XV. Dissolution of tablets T3, T5 and T6 in 
"near - sink" conditions ...•....................... 71 
( 
viii 
LIST OF FIGURES 
( 
Page 
1. Photodecomposition and biotransformation scheme ...... 3 
2. UVabsorptionspectrumofnifedipineandits 
photodecomposition product ........................... 36 
3. A typical HPLC chromatogram showing nifedipine 
and its photodecomposition product ................... 47 
4. HPLC calibration curve using peak heights ............ 48 
5. HPLC calibration curve using peak areas .............. 49 
6. UV calibration curve for nifedipine (238 nm) ......... 50 
7. Rate of photodecomposition of nifedipine 
showing first order decay ............................ 53 
8. Dissolution profiles of formulations under 
non - sink conditions .............•.................. 63 
9. Dissolution profiles of formulations under 
"near sink" conditions .....•......................... 73 
ix 
( 
I. INTRODUCTION 
1. NIFEDIPINE 
Nifedipine, a dihydropyridine derivative is one of a 
group of compounds thought to act by blocking the transmem-
brane inward movement of calcium. It has been shown to be an 
effective and relatively well tolerated treatment for stab-
le, variant and unstable angina, mild to severe hyperten-
sion, and Raynaud's phenomenon (93). 
Clinical trials support the view that nifedipine can be 
considered a first line choice in all grades of angina, 
especially when coronary vasospasm is the underlying cause 
or when hypertension and / or congestive heart failure are 
added complications. Nifedipine also appears to be particu-
larly useful in clinical situations when a rapid lowering 
of elevated blood pressure is needed, and there is growing 
evidence that it is an effective and safe choice for the 
long term management of patients with mild to moderate 
hypertension (93). 
However, the majority of data have been from medium 
term studies, and confirmation of its long term usefulness 
in well designed trials is still required. Additionally, it 
has convincingly been shown to be a useful adjunct to con-
trolling blood pressure in patients refractory to conventio-
nal treatment with beta blockers, diuretics and various 
vasodilators (12,32). Nifedipine reduces the number, dura-
tion and severity of vasospastic attacks in more than 60% of 
1 
( 
patients with Raynaud's phenomenon of varying etiology, and 
in individual cases it apparently facilitates the healing of 
digital ulcers. 
Thus nifedipine is a worthwhile alternative to other 
drugs available for the treatment of the various forms of 
angina, acute episodes of hypertension, mild to severe hype-
rtension (18,23,24,35,50,63,67,84,103) and Raynaud's pheno-
menon (22). 
PHARMACOKINETICS : 
Few well designed studies have been performed that 
adequately describes pharmacokinetic properties of nifedi-
pine. The paucity of information detailing the kinetic as-
pects of nifedipine is due primarily to two factors (93). 
Firstly, until recently no parenteral dosage form was 
commercially available, and laboratory preparation of a 
solution for intravenous pharmacokinetic studies was diff i-
cult due to the photosensitive nature of such solutions. 
Nifedipine is very light sensitive and breaks down rapidly 
on exposure to daylight, tungsten bulb light, standard fluo-
rescent light or ultraviolet irradiation to its more stable 
nitroso or nitropyridine (see fig.l) derivatives 
(6,21,37,52). Nifedipine is stable, however, when "gold" 
fluorescent light is used (37). 
Secondly, there have been problems in developing a 
sufficiently sensitive and specific method for analysis of 
nifedipine plasma concentrations after therapeutic doses. 
Although the concentrations of nifedipine in body fluids has 
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Fig. 1. Photodecomposition and biotransformation scheme. I is 
nifedipine; p-I and p-II are photodegradation products 
and M-I and M-II are metabolites (from ref. 52). 
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been determined by radioisotope (93), high performance li-
quid chromatograghy (51,52, 64,74), gas chromatography 
(21,48), fluorimetry (55) and mass spectrometry (40), the 
various discrepancies reported for nifedipine pharmacokine-
tic parameters may originate in part from the inefficiency 
of some of these assay techniques in distinguishing parent 
from its inactive metabolites and photodegradation products 
(93) . 
Clinical studies have shown that the hypotensive effect 
of nifedipine could be correlated with the plasma drug 
concenration (4,7,55). The absorption of nifedipine, howe-
ver, is poor when administered orally in a solid dosage form 
(96) because of its poor water solubility. Several studies 
reported that the nif edipine plasma levels increased rapidly 
after oral administration of commercially available (soft 
capsule) water soluble formulations (29,78) with peak plasma 
concentrations occuring after about 30 minutes of adminis-
tration. With sublingual administration the peak occured 
after 1 hour (78). The half - life of elimination from the 
commercial capsule was only about 3.5 hours (29). Consequen-
tly, the antihypertensive effects of nifedipine lasts only 
for a few hours which restricts its use in treating chronic 
hypertension (101). On the other hand Taburet et al (100) 
administered a tablet formulation with crystalline form of 
nifedipine to hypertensive men and found that the resulting 
tmax from the tablets was about 2 hours with an elimination 
half life of about 10 hours. These values did not differ 
4 
between doses of 20, 40, and 60 milligrams. 
From these studies it is clear that in order to opti-
mize the delivery of nifedipine a dosage form must be deve-
loped which releases the drug quickly (i.e. has a high 
dissolution rate) while maintaining a longer elimination 
half life. 
2. ENHANCEMENT OF DISSOLUTION RATE 
The following section describes briefly the various 
methods used for enhancing the dissolution rate of drugs in 
solid dosage forms. The basis of these methods is the Noyes 
- Whitney equation modified by Underwood and Cadwalla-
der (105): 
(1) 
where dW/dt is the dissolution rate, K is a dissolution 
constant, S is the surface area of the solid, Csat is the 
concentration of the saturated solution and Csol the concen-
tration at any given time. 
2.1. USE OF SURFACTANTS 
Surfactant adsorption onto hydrophobic drug particles 
below the critical micelle concentration can aid in wetting 
of the particles and consequently increase the rate of 
solution of particulate agglomerates (31,60,79,89). Surfac-
tants may be incorporated into solid dosage forms (26) so 
that their solubilization action comes into play as disinte-
gration process starts and water penetrates to form a conce-
ntrated surfactant solution around the drug particles or 
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granules. Both facilitation of wetting through lowering of 
surface tension and solubility increase will aid in dissolu-
tion of the drug. Other techniques of incorporating surf ace 
- active agents have been reported. Chiou et al (13) have 
discussed the enhancement of dissoltion of poorly water 
soluble drugs by crystallization in aqueous surfactant solu-
tions. Ford and Rubinstein (28) have discussed the dissolu-
tion characteristics of a glutethimide - nonionic surfactant 
melt system. 
Surfactants cannot be considered to be "inert" pharma-
ceutical adjuvants which can be used indiscriminately in 
formulations. Even nonionic surfactants which are generally 
more acceptable than ionic surfactants because of their 
lower toxicity are not without intrinsic biological activity 
of their own (27) which can be ascribed to their affinity 
for and action on biological membranes. 
Apart from their own biological or toxicological ef-
fects nonionic surfactants can sometimes act synergistically 
with a drug substance to promote its absorption or activity, 
or may decrease activity by entrapping the drug in micelles 
which diffuse slowly and which cannot cross cell membranes 
intact. 
In any dosage form in which dissoution is the rate 
limiting step prior to drug absorption, surfactants can, by 
increasing the dissolution rate, increase the bioavaialabi-
li ty without any effects on the barrier properties of the 
boundary membranes. However, if the surfactant does modify 
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the permeabilty of the membranes, then any observed effect 
on bioavailability is likely to be the result of both a 
physical and a biological effect. Above the critical micelle 
concentration, there is the added complication of partitio-
ning of lipophilic drugs into micelles. The measured effect 
of solubilzer will then be the result of these processes: 
(1) increase in wetting and dissolution rate, 
(2) increased permeability of biological membranes, and 
(3) solubilization. 
The efffect of the first two is to inrease and the last 
to decrease absorption, although at very high solubilizer 
concentrations solubilization occurs of those components 
such as cholesterol and protein, essential for the integrety 
of the membrane, causing a marked increase in drug absor-
ption (26). 
2.2. SOLID STATE MANIPULATION 
Many compounds exist or are capable of being manipu-
lated to exist in more than one form as solids. Some of 
these forms are crystalline phases while others are metasta-
ble states where the compound is a noncrystalline or molecu-
larly dispersed form. Pharmaceutical scientists have been 
making use of the differences in the physical chemical 
properties that exist between these solid states to optimize 
drug delivery. Some of the ways in which the solubility 
characteristics are modified by the solid state modification 
are discussed. 
7 
2. 2 .1. POLYMORPHISM 
The ability of many compounds to crystallize in more 
than one crystal form is known as polymorphism and has been 
rewiewed by Haleblian (36). The solubility of each form 
depends on the ability of the molecules to escape from the 
crystal of the solvent. The stable form possesses the lower 
free energy at a particular temperature and pressure and 
therefore has the lower solubility or escaping tendency. 
When a metastable form is placed in contact with sol-
vents, it can rapidly undergo reversion to the more stable 
crystal form. The transformation process in such an environ-
ment will depend to a great measure on the degree of super-
saturation achieved by the metastable material. There are 
also instances in which adsorbed water on the surface of the 
solid will catalyse the transformation process (87). 
Using polymorphic modifications a 50 - 100 % increase 
in dissolution rate can be realistically achieved 
(16,44,87). However for some drugs a four fold increase has 
been achieved (1,58). The amporphous form of novobiocin (69) 
and sulfa drugs (66,92) have been isolated and found to be 
much more soluble than the respective crystalline form. In 
case of novobiocin the amporphous form was 10 - fold more 
soluble than the crystalline drug (69). 
2. 2. 2. SOLVATES 
Many drug compounds upon recrystallization retain a 
stoichiometric amount of the solvent. These crystalline 
materials, referred to as solvates or pseudomorphs, may be 
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looked upon as molecular complexes. An important class of 
solvates are the hydrates which contain water. In an aqueous 
environment these compounds are the most stable forms and 
therefore have lower solubilities in aqueous solvents than 
the anhydrous (crystalline or noncrystalline) forms. When 
the solvent is not water, the solvent may dissociate in 
aqueous environment, and, depending upon the solubility 
product for the solvate in the media, the concentration of 
the drug in the solution may well reach a level much greater 
than that attainable from a nonsolvated form of the drug. 
Shefter and Higuchi (88) studied the dissolution of the 
pentanol solvate of succinyl sulfathiazole and found an 
eightfold increase in solubility over the hydrate. However 
the nature of the bound solvent in the crystal and the 
ability of the dissolution media to dissociate the solvent 
dictates the extent to which there will be a favorable 
effect. 
2.2.3. RACEMATES AND ENANTIOMERS 
The racemates and enantiomeric forms of a compound may 
differ substantially in their solubilities (59,81). If, in 
addition to possessing higher solubility (and hence dissolu-
tion rate), an enantiomer is more active biologically than 
the racemate then attempts should be made to isolate the 
enantiomer and this should be used in the formulation. 
2.2.4. REDUCTION OF PARTICLE SIZE 
The effect of particle size reduction of drugs on their 
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dissolution rates and biological availability was reviewed 
comprehensivly by Fincher (25). A reduction in particle size 
of drugs leads to an increase in the total surface area (S) 
and the Noyes - Whitney equation predicts that this will 
result in an increase in dissolution rate. For drugs with 
poor water solubility a reduction in particle size generally 
increases the rate of absorption and /or total bioavailabi-
li ty. For example, the therapeutic dose of griseofulvin was 
reduced to 50% by micronization (5) and a more constant and 
reliable blood level was produced. The commercial dose of 
spironolactone was also decreased to a fourth by just a 
slight reduction of particle size (56). Such enhancement of 
drug absorption could further be increased several folds if 
a micronized product was used (8,56). 
Partical size reduction is usually achieved by one of 
the following methods (4) : (a) conventional trituration 
and grinding; (b) ball milling; (c) fluid energy microniza-
tion (d) controlled precipitation by change of solvent or 
temperature, application of ultrasound waves, and spray 
drying; (e) administration of liquid solutions from which, 
upon dilution with gastric fluids, the dissolved drug may 
precipitate out in very fine particles; and (f) adminis-
tration of water soluble salts of poorly soluble compounds 
from which the parent, neutral forms may precipitate in 
ultrafine form in the GI tract. 
Although the reduction of particle size can be easily 
accomplished by the first four (a-d), the resultant fine 
10 
( particles may not produce the expected faster dissolution 
and absorption. This primarily results from the possible 
aggregation and agglomeration of the fine particles due to 
their increased surface energy and the subsequent shorter 
van der Waal's attraction between nonpolar molecules. Anot-
her inherent disadvantage of these pure fine powders of 
poorly soluble drugs is their poor wettability. For these 
reasons the methods mentioned above are seldom used for 
dissolution rate enhancement. 
2.2.5. SOLID DISPERSIONS 
The term "Solid Dispersions" was defined by Chiou and 
Riegelman (14) and refers to "the dispersion of one or more 
active ingredients in an inert carrier or matrix at solid 
state, prepared by the melting, solvent or melting - solvent 
method." Not included in this category are the dispersions 
of drugs in solid diluents by the traditional mechanical 
mixing (9). 
The selection of the matrix has an ultimate influence 
on the dissolution characteristics of the dispersed drug. A 
poorly water soluble drug combined with a water soluble 
carrier results in a fast release of the drug. On the other 
hand the release of a water soluble drug can be retarded by 
the use of a water - insoluble matrix. 
Two basic procedures are used to prepare solid disper-
sions: fusion and cosolvent techniques. Modification of 
these methods and combinations of them have also been used 
for the preparation of dispersed systems (14). 
11 
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The fusion technique involves the heating the compo-
nents which make up the dispersion (drug plus carrier) to a 
temperature at which melting occurs and a solution forms. 
The melted mixture is usually cooled rapidly to entrap the 
drug particles in the matrix in a very fine state. The 
cooling rate of the mixture can influence the physical state 
of the solid obtained and the particle size of the crystals 
formed (87). The principal disadvantage of this procedure is 
the possibility of decomposition and / or evaporation of a 
component at the elevated temperatures required. Low melting 
polyethylene glycols are used commonly as carriers (9). 
The cosolvent approach involves dissolving the in-
gredients comprising the dispersion in a common solvent. The 
solvent is then evaporated off with the aid of a vacuum 
pump. Sometimes heat is used to assist in the evaporation of 
the solvent. Materials prepared by this procedure are some-
times known as ~Q£reci2..!tate§. (14). The ingredients of the 
dispersion should be very soluble in the solvent, or crysta-
llization of one may take place before the other and a 
uniform dispersion will be derived. 
In many instances it is difficult to completely remove 
the solvent from the dispersion. This in turn may have an 
effect on the stability of the dispersion, both chemical and 
physical. 
Solid dispersions are generally of the following four 
types: eutectics, polymeric systems, glass dispersions, and 
solid surface dispersions. 
12 
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(a) ~utectics: Eutectics are prepared by rapid solidifica-
tion of two melted components which show complete miscibili-
ty in the liquid state. A number of systems exhibiting 
eutectic behaviour have been examined. Urea and succinic 
acid have been found to form simple eutectics with a wide 
variety of drugs. This approach was first demonstrated by 
Sekiguchi and Obi (85) in 1961 for formation of a eutectic 
mixture of sulfathiazole with urea to increase dissolution 
rate and absorption. 
The increase in dissolution rate observed for eutectic 
mixtures can result from a number of factors. The main 
causes postulated (87) for the observed dissolution of of 
these systems are as follows: 
(i) The particle size of the drug in the eutectics formed by 
rapid solidification will be small. This can result in an 
enhanced dissolution rate as a result of both surface area 
increase and solubilization. 
(ii) The carrier material as it dissolves may have a solubi-
lizing effect on the drug. 
(iii) In a eutectic where each crystallite of drug is sur-
rounded by a water soluble crystal, there will be good 
wettability and dispersibility of the drug in the dissolu-
tion media. The enhanced wettability of the drug should 
retard any agglomeration and aggregation of the particles 
which can slow the dissolution process. 
(iv) The process of eutectic formation may cause the drug to 
crystallize in a metastable state. As indicated earlier, 
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these phases in themselves would have a greater solubility 
and therefore result in faster dissolution rates. 
(b) Roly~eric .e.yste~s: Water soluble polymers have been 
extensively used to form solid dispersions. Most of the 
reported investigations have focussed on dispersions made 
with polyethylene glycols or PVP. Studies with these polyme-
ric substances (14) indicate that the ratio of drug to 
polymer should be low to maximize the increase in dissolu-
tion of the drug. PVP is a noncrystalline polymer able in 
many instances to disperse a significant amount of a drug in 
a "high energy form" (61,83,91,95). The amount of drug which 
can be loaded into PVP as a high energy noncrystalline form 
is a function of the structure of the drug and the cosolvent 
used to prepare the coprecipitate (87). In some instances, 
the drug could be loaded into the polymer such that it would 
exist almost exclusively in the higher energy state as long 
as the ratio of drug to PVP was less than one (87). 
Inhibition of the growth of the drug crystal structure 
by PVP in solid dispersions (20) has been linked to improved 
dissolution behaviour (19,90,92) and the formation of highly 
supersaturated drug solutions (19,62). The implication is 
that PVP prevents drug crystallization during preparation by 
a drug polymer interaction, possibly involving hydrogen 
bonding, in the liquid state (86,91). Once the solvent is 
removed, the interaction helps stabilize the amorphous high 
energy state ( 4 7). 
The degree of solubilization observed for these systems 
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is usually high. Reports of 6 to 10 fold increases in 
solubility is not uncommon. An interesting facet of these 
dispersions is that the high solubility achieved is main-
tained in solution for long periods of time (83,90,95). 
High molecular weight PEG's which are highly crystal-
line in nature, are believed to be capable of entrapping low 
molecular weight compounds in their interstitial spaces 
(14). When PEG dispersions are prepared with their drug 
fractions greater than their "solid solubility", ultrafine 
suspensions of the drug are produced. Although these disper-
sions exhibit much faster dissolution rates than the pure 
drug, they are relatively slower dissolving than those dis-
persions containing the drug in its molecularly dispersed 
form. 
(c) Glass Dispersions: A number of water soluble compounds 
are known to form glasses when their melts are rapidly 
solidified. Among these are citric acid and a host of su-
gars. The glassy or vitreous state is characterized by 
transparency and brittleness below the glass forming tempe-
rature. On heating, it softens progressively and continuous-
ly without a sharp melting point. This is primarily due to 
the fact that the chemical bonds in the glass differ consi-
derably in length and, therefore, in strength and that there 
is no one temperature at which all the bonds become loosened 
simultaneously (14). The lower density of glasses resulting 
from molecular framework in the glasses could provide the 
environment for the dispersal of drug molecules. Such dis-
15 
( persions would be expected to rapidly dissolve in aqueous 
media. Drugs dispersed in glass matrices of dextrose, galac-
tose, and sucrose have been reported to exhibit very rapid 
dissolution rates (2). Examples of glass solutions are pri-
midone - citric acid (97), griseofulvin - citric acid and 
phenobarbital - citric acid (9). 
(d) Solid Surface Dispersions: The dissolution characteris-
tics of drugs can be altered by dispersing it on the surface 
of certain materials. Deposition of the drug by solvents on 
solid supports and by grinding it with certain materials has 
produced dramatic results. 
Monkhouse and Lach (65) used water - insoluble adsor-
bents, such as fumed silicon dioxide and silicic acid, as 
supports for the solvent deposition of a number of drugs. 
The support material is suspended in a solution of the drug 
followed by evaporation of the solvent. The resulting mate-
rial contained the drug in a "molecularly micronized" state 
on the surface of the carrier. 
Yamamoto et al (106) observed that when griseofulvin 
was ground with microcrystalline cellulose in a vibrational 
ball mill its dissolution rate and bioavailability were 
substantially enhanced. The grinding procedure was shown to 
result in a total loss of griseofulvin crystallinity. Other 
drugs which have been dispersed similarly on microcrystal-
line cellulose are aspirin, salicylic acid, chloramphenicol 
palmitate, diazepam, mefenamic acid and sulfisomezole (70). 
Another approach for dispersing drug on solid surfaces 
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is the roll - mixing method of Nozawa et al (72,73). This 
method was shown to enhance the dissolution rate of pheny-
toin (72) and nifedipine (73). 
2.3. COMPLEX FORMATION 
The alteration of apparent solubility which can be 
achieved through complexation may be utilized to decrease or 
to increase solubility. The usefulness of the solid complex 
obtained will be dependent upon its apparent solubility 
relative to that of the inherent solubility of the sub-
strate. For instance, Higuchi and Pitman (43) have suggested 
the use of a relatively insoluble caffeine - gentisic acid 
complex for reducing the bitterness of caffeine in a chewab-
le tablet. However the more common use of solid complexes is 
associated with the enhanced solubility of the complex. 
An example of a system in which the use of solid com-
plex has been found to substantially enhance dissolution 
rate is the digoxin - hydroquinone system (42). The dissolu-
tion rate of digoxin from the complex (two mols digoxin : 
three mols hydroquinone) was much more rapid and complete 
than that of digoxin when powders of equal mesh size and 
equal digoxin concentrations were compared. 
Another example of enhanced dissolution rate through 
the use of complex is the 1:1 acetaminophen - caffeine 
complex (15). It was found that the solid complex at 25 
degrees Celcius was a hexahydrate form. However, when the 
complex was dried to yield either the monohydrate or anhyd-
17 
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rous complex, the apparent solubilities and the associated 
dissolution rates of both these species were much greater 
than with the hexahydrate complex of pure acetaminophen. 
These results point out the need to carefully characterize 
the nature of the solid complex for the extent of solvation, 
as well as the substrate - ligand stoichiometry, before 
reaching any conclusion about the usefulness of the complex 
( 80) • 
The use of complexation has several advantages. Among 
these are the reversibility of the interactions. Dissocia-
tion of the complex to the individual reactants occurs 
rapidly and spontaneously upon dilution. Consequently, the 
biological effects of complexes can be predicted on the 
basis of the knowledge of the pharmacologic properties of 
each of the interactants. The above characteristics of the 
complexes are in contrast to chemically derived prodrugs 
which normally require some sort of "triggering" features to 
aid in release of the parent drug. Another advantage of the 
use of complexation is the physical stability of these 
systems in comparison with polymorphs and other crystal 
modification which are often thermodynamically unstable and 
therefore may undergo time - dependent changes in solubility 
behavior. 
This approach, however, is not without limitations. 
Ironically, in some instances, it may be that rapid and 
total reversibility previously presented as an advantage may 
prove to be a problem especially in those cases in which 
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dilution of a system may result in precipitation. 
A second problem is the necessary presence of the 
ligand whose sensory and/or pharmacologic effects may be 
unacceptable. 
Finally, in most reported cases, the apparent solubili-
ty increases realized by complexation were an order of 
magnitude or less (80). Consequently, when solubility in-
creases of 10 2 or 10 3 are required, approaches other than 
complexation should be used. 
2.4. FORMATION OF INCLUSION COMPOUNDS 
Inclusion compounds are addition compounds in which one 
entity fits into and is surrounded by the crystal lattice of 
the other (17). These are complexes characterized by the 
lack of adhesive forces between the components of the com-
plex. It is not a chemical interaction which causes an 
inclusion compound to form, although this may be a factor in 
the net complexation observed. The steric configurations of 
the molecules are such that the enclosing, or "host" mole-
cule, can spatially enclose the included or "guest" mole-
cule, leaving unaffected the bonding systems of the compo-
nent. Thus geometrical rather than chemical characteristics 
of the molecules are the limiting factors in the interaction 
( 17) . 
The formation of inclusion complexes of a drug with 
nontoxic agents is a type of manipulation used to improve 
the dissolution properties of drugs (30,104). Cyclodextrins, 
which are products of enzymatic degradation of starch, have 
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been used extensively as such complexing agents. In these 
complexes molecules of the drug are enclosed in the hydrop-
hobic cavity of a cyclodextrin molecule or in a channel 
formed by several molecules of cyclodextrins. Depending on 
the size of the open space within each molecule the cylodex-
trins have been classified as alpha, beta and gamma. 
Because of their different internal ring sizes the 
cyclodextrins show different degrees of inclusion formation 
with different sized molecules. Beta cyclodextrin, which is 
the most practical to use, unfortunately has low water 
solubility, and its complexes are also often only slightly 
soluble. Recently attempts have been made to improve the 
solubility of beta cyclodextrin by chemical derivatization 
(68, 71, 75, 77). 
However, there have been only a limited number of 
studies to indicate the lack of toxicity of these new com-
pounds in humans and much more work is needed before these 
compounds can be used in commercial products. 
2.5. DRUG DERIVATIZATION 
The use of derivatives to enhance the aqueous solubili-
ty of insoluble drugs and has long been recognized as an 
effective design strategy. The prodrug strategy is based on 
chemical or biochemical reconversion to the active drug 
prior to reaching the site of action. 
Generally two strategies can be used to increase the 
aqueous solubility : (a) introduction of an ionic or ioniza-
ble group and (b) introduction of a group which decreases 
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the melting point. 
The synthesis of an ionic or ionizable derivative of a 
drug is perhaps the most common of the prodrug strategies. 
Some of the progroups used are hemisuccinates, phosphates, 
dimethylaminoacetates, amino acid esters, choline esters, 
and betadimethylaminoethyl esters (3). 
Examples of increases in solubility by lowering the 
melting point are seen in allopurinol (46) and ara-A (82). 
The basis for this strategy is that in order to dissolve, 
molecules must be removed from the crystal lattice. Any 
modification which reduces the crystal lattice energy, hence 
melting point, would tend to increase solubility (in all 
solvents). The relationship between the aqueous solubility 
Sw and melting point is expressed by the equation (3): 
logSw = -logPC - O.OlMP + 0.5 (2) 
where PC is the octanol/water partition coefficient and MP 
the melting point in degrees Celcius. 
3. CONTROLLED RELEASE DOSAGE FORMS 
A controlled release dosage form is generally defined 
as one that attempts to (57): 
(1) sustain drug action at a predetermined rate by maintai-
ning a relatively constant, effective drug level in the body 
with concomitant minimization of undesirable side effects 
associated with a sawtooth kinetic pattern. 
(2) localize drug action by spatial placement of a control-
led release system adjacent to or in the diseased tissue or 
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organ. 
(3) target drug action by using carriers ar chemical deriva-
ti zation to deliver drugs to a particular "target" cell 
type. 
In practice, very few of the applied systems embrace 
all of these actions. In most cases, the release system 
creates constant concentration of drug within the body over 
an extended period of time. It is desirable that the dura-
tion of drug action become more a design property of a rate 
controlled dosage form, and less, or not at all, a property 
of the drug molecule's inherent kinetic property. 
3.1. ORAL CONTROLLED RELEASE SYSTEMS 
Oral ingestion has long been the most convenient and 
commonly used route of drug delivery. Indeed, for sustained 
- release systems, the oral route of administration has by 
far received the most attention with respect to research on 
physiological and drug constraints as well as design and 
testing of products. This is because there is more flexibi-
lity in dosage form design for the oral route than there is 
for other routes. 
As in the case for systems for nonoral routes, the 
design of oral sustained release delivery systems is subject 
to several intercalated variables of considerable importan-
ce. Among these are the type of delivery system, the physi-
cochemical property of the drug, the disease being treated, 
the patient factors and the length of therapy. 
The majority of oral controlled release systems are 
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either tablets or capsules although a few liquid products 
are also available. Sustained release tablets and capsules 
usually consist of two parts : an immediately available dose 
to establish the blood level quickly and a sustaining part 
that contains several times the therapeutic dose for protra-
cted drug levels. Several approaches are available to add 
the immediately available dose to the sustaining part. Sim-
ple addition of a nonsustained dose of a drug to a capsule 
or tablet is the most direct method; placement of the ini-
tial dose in the tablet coat with the sustaining portion in 
the core represents the alternate approach. Potential physi-
cal methods that can be used to retard drug release are 
summarized below (42): 
1. Capsules of polymeric material filled with a solid or 
liquid drug or with a suspension of drug in a fluid, in 
which drug release is controlled by diffusion through the 
capsule wall 
2. A heterogeneos dispersion of drug particles in a solid 
matrix which can be either biodegradable or nonbiodegradable 
and which controls drug release by diffusion through the 
matrix, by erosion of the matrix, or by a combination of 
both diffusion and erosion 
3. A laminate of agent and polymeric material made by coa-
ting a film of biodegradable or nonbiodegradable material 
with solid drug and then by forming the film into a sealed 
"sandwich" or "jellyroll", in which drug release is by 
diffusion, erosion, or both 
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4. A heterogeneous dispersion or solution of drug in a water 
- swellable hydrogel matrix, which controls drug release by 
slow surface-to-center swelling of the matrix by water and 
subsequent diffusion of the drug from water-swollen part of 
the matrix 
5. Liquid-liquid encapsulation of the drug in a viscous 
solution of polymer, which controls drug release by slow 
diffusion through dilution of the media 
6. Pumps that either mechanically or chemically (osmotic 
pressure) provide drug in a controlled manner 
7. Drug coated micropellets which have an apparent density 
lower than that of gastric juice for an extended period, 
while slowly releasing drug 
8. Drug-containing bioadhesive polymer that adheres to the 
mucin coating of the GI tract and which is retained on the 
surface epithelium to extend GI transit time of the drug. 
Drug is released at a constant rate from the bioadhesive 
polymer for subsequent absorption 
9. Chemical bonding of a drug to a polymer backbone by 
pendent amide or ester linkages, which controls drug release 
by hydrolysis 
10. Formation of macromolecular structures of the drug via 
ionic or covalent linkages, which controls drug release by 
hydrolysis, thermodynamic dissociation, or microbial degra-
dation 
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3.2. POLYMERS IN ORAL CONTROLLED RELEASE SYSETEMS 
Other than mechanical pumps, all controlled release 
devices use polymers in the rate control mechanism. Polyme-
ric devices can be classified into 3 categories: (a) diffu-
sion-controlled devices, (b) solvent-controlled devices, and 
(c) chemically-controlled devices. Of these, the first two 
types are used for oral drug delivery while the chemically 
controlled devices are usually employed for implantable 
systems or other non-oral systems and will not be discussed 
here. 
3.2.1. DIFFUSION CONTROLLED DEVICES 
These may be further classified into monolithic devices 
and reservoir devices. 
In a monolithic device the therapeutic agent is intima-
tely mixed (either dissolved or dispersed) in a rate contro-
lling polymer, and release occurs by diffusion of the agent 
from the device. For an active agent dissolved in the mat-
rix, release kinetics can be calculated by two equtaions 
(39). Equation (3), known as the early time approximation, 
holds true for the first 60% of the release rate, after 
which it is calculated from eq.(4), which is known as the 
late time approximation. 
dMt/dt = 2Mx(D/pi.l 2t) 1/2 
dMt/dt = (8DMx/1 2 ) exp (-pi2Dt/1 2) 
(3) 
(4) 
These equations predict active agent release from a 
slab of thickness 1 where D is the diffusion coefficient, Mx 
is the total amount of active agent dissolved in the polymer 
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and Mt is the amount released at a time t. As equation (3) 
shows, release rate decreases as t-1/ 2 over the first 60% of 
the release; over the remainder of the release the rate 
decays exponentially according to eq. (4). 
When the active agent is dispersed in a the polymer, 
release kinetics have been derived by Higuchi (41): 
(5) 
where A is the area, Cs is the solubility of the active 
agent in the matrix and c0 is total concentration in the 
matrix (dissolved plus dispersed) . 
Although active agent release from monolithic systems 
does not proceed by zero-order kinetics, it is the simplest 
and most convenient way to achieve prolonged release of an 
active agent. 
In a reservoir device the active agent is contained in 
a core that is surrounded by a rate controlling membrane. 
Transport of the material in the core through surrounding 
nonporous, homogeneous polymer film occurs by dissolution at 
one interface of the membrane and then diffusion down a 
gradient in thermodynamic activity (39). It can be described 
by Fick's first law modified: 
J = -DKC' I 1 (6) 
where J is the flux, D is the diffusion coefficient of the 
permeant in the membrane, C' is the concentration difference 
between solutions on either side of the membrane, K is the 
distribution coefficient analogous to a liquid - liquid 
partition coefficient and 1 is the thickness of the membrane. 
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If the thermodynamic activity of the active agent in 
the reservoir remains constant, if there is no change in the 
rate - limiting membrane characteristics, and if infinite 
sink conditions are maintained at the downstream side of the 
membrane, rate of active agent release will be constant and 
can be predicted from a knowledge of membrane permeability 
and device configuration. 
Even though such reservoir type devices should theore-
tically be capable of delivering active agents at a constant 
rate, also referred to as zero-order kinetics, in practice 
several factors contribute to deviations from zero-order 
kinetics. The two most important factors are boundary layer 
effects and the burst effect. 
Boundary layer problems arise in applications in which 
the rate of removal of the active agent from the membrane is 
slow so that the concentration of the drug at the membrane 
surface increases with time. Then as predicted by eq.(6), 
the term dC decreases and consequently the flux J also 
decreases. 
Burst effects occur when during storage the active 
agent contained in the core saturates the membrane surroun-
ding the core; then, when the device is placed in the desor-
bing medium, the active agent will rapidly desorb from the 
membrane. 
Reservoir devices are capable of very long term zero-
order drug delivery. However they may require more complex 
fabrication procedures than monolithic devices. 
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3.2.2. SOLVENT-CONTROLLED DEVICES 
Solvent-controlled devices release active agents as a 
consequence of controlled penetration of a solvent into the 
device. Although non-aqueous solvents can be used, only 
water is of importance in controlled release applications 
for human or veterinary applications. The two general mecha-
nisms used for solvent-controlled devices are osmosis and 
swelling. 
a. Q~~otical.J:y-Controlleg _Qevices: In these devices the 
active agent is placed in an innermost impermeable flexible 
reservoir surrounded with an osmotic agent, which in turn is 
surrounded with and sealed within a rigid cellulose acetate 
semipermeable membrane (39). When the device is placed in an 
aqueos environment, water is osmotically imbibed across the 
semipermeable membrane, and the active agent contained wit-
hin the flexible reservoir is pumped out of the device. 
Because the driving force is the osmotic transport of water 
across the membrane, performance of the device is essential-
ly independent of the environment within which the pump 
operates. 
b. Swelling-Controlled Devices: In these systems an active 
agent is homogeneosly dispersed in a glassy polymer. Because 
glassy polymers are essentially impermeable, the active 
agent is immobilized in the matrix, and no diffusion through 
the solid polymer phase takes place. 
When such a monolithic device is placed in an aqueous 
environment, water begins to penetrate the matrix and swel-
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ling takes place. As a consequence, chain relaxation takes 
place and the incorporated active agent begins to diffuse 
from the swollen layer. 
29 
( 
II. PURPOSE OF THIS STUDY 
As can be seen from the preceding discusion, it would 
be desirable to formulate an oral solid dosage form, prefe-
rably a tablet, offering some degree of control over the 
release of nifedipine. The final properties will be influen-
ced by the techniques used for enhancing the dissolution 
rate, by the material and proportion of the rate - control-
ling matrix, and by the tablet properties (hardness, disin-
tegration, etc) . 
For the enhancement of dissolution of nifedipine in the 
present study, the solid dispersion technique has been em-
ployed using PEG 8000 and PVP 40T as the polymer for forming 
coprecipitates. In a preliminary study Sugimoto et al (96) 
found that nifedipine - PVP coprecipitates gave the fastest 
release rates. Further, the molecular weight of PVP that 
gave the best results was 40,000. Compared to the bioa-
vailability from a physical mixture (of nifedipine and PVP) 
the Cmax and AUC of the coprecipi tates were 5 - fold and 3 -
fold higher. 
The rationale for using PEG for preparing coprecipi-
tates is the fact that the physicochemical stability of PEG 
coprecipitates are very high (99). The use of PEG 8000 for 
the preparation of nifedipine coprecipitates is not reported 
in the literature. However, Sumnu (98) found no significant 
differences between PEG 4000, 6000, and 10000 when release 
of nifedipine coprecipitates with these substances were 
compared. 
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For sustaining the release, powdered microporous polyp-
ropylene polymer (Accurel) has been used. This new material 
has small cells and canals formed throughout its structures 
which are connected by small pores occupying 30 - 90% of the 
volume (49,94). For this study, powdered polypropylene con-
taining 75% v/v void space has been used. A major advantage 
of this substance is its property to give good coherence 
after tabletting (49). Matrix tablet with relatively high 
drug load show diffusion controlled characteristics and 
release was approximately zero - order (49). 
The objectives of this study were : 
1. To prepare an optimized formulation of nif edipine using 
the coprecipitate approach to improve the dissolution rate. 
2. To study the tabletting properties of the variuos formu-
lations. 
3. To perform in ~itro dissolution tests to evaluate the 
release rate of nifedipine from the tablet dosage forms. It 
is desired that about 50% of the dose (i.e. 10 mg) be 
released within 20 minutes and the remaining 50% be released 
over an extended period of time (compared to the release of 
commercial soft gelatin capsules under similar conditions). 
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III. EXPERIMENTAL 
1. MATERIALS 
A. Chemicals 
Acetic acid, Glacial Reagent A.C.S. (lot # 705283) 1 
Accurel, Polypropylene powder, 75% void space (lot # 
40306/1-3/P) 2 
Ac-di-sol TM, Type SD - 711, modified cellulose gum 
(lot # 7135 - 25) 3 
Acetonitrile HPLC grade (lot # 853747) 1 
Ammonium acetate (lot # 731745) 1 
Cab-0-Sil brand colloidal silica4 
Ethanol 200 proof, Dehydrated alcohol u.s.P5 . 
Hydrochloric acid6 
Methanol HPLC grade (lot # 864444 & 863081) 1 
Polyethylene glycol 8000 (lot# 106 F - 0020) 7 
Polyvinyl pyrrolidone, PVP - 40T (lot# 74F-0208) 7 
Phosphoric acid HPLC grade (lot # 715056) 1 
Potassium phosphate monobasic (lot # 722964) 1 
Potassium phosphate dibasic (lot # 722337) 1 
Sodium hydroxide, Certified A.C.S. (lot # 720859) 1 
Sodium phosphate dibasic (lot # 772374) 1 
Sodium lauryl sulfate, u.s.P. 
B. Dr~~ 
Nifedipine crystalline powder (batch # 167707A) 8 
Nifedipine soft - gelatin capsules (Adalat) 8 
1. Fisher Scientific Company, Fairlawn, New Jersey. 
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2. Enka Industrial Products Inc., Illinois. 
3. FMC Corporation, Philadelphia, Pennsylvania. 
4. Cabot Corporation, Boston, Massachusetts. 
5. U.S. Industrial Chemical Company, Tuscola, Ill. 
6. E.I. du Pont de Nemours & Co., Wilmington, Del. 
7. Sigma Chemical Company, St. Louis, Missouri. 
8. Bayer AG., Germany; supplied by Miles Pharma-
ceuticals, West Haven, Connecticut. 
2. EQUIPMENT 
Electronic Analytical Balance, Sartorus GMBH, Germany. 
Electrical Balance, Model HS Mettler, Will Scientific 
Inc., Rochester, New York. 
Dissolution Tester Six Spindle, Vanderkamp 600, Van-kel 
Industries Inc., Chatham, New Jersey. 
Tablet Disintegration Test Apparatus, Van-kel Industries 
Inc., New Jersey. 
HPLC Solvent Delivery System Model 6000A, Waters Asso-
ciates, Milford, Massachusetts. 
WISP 710B, Waters Associates, Milford, Massachusetts. 
mu- Bondapak Cl8 Column, Waters Associates, Milford, 
Massachusetts. 
LC Spectrophotometer Lambda Max Model 480, Waters Asso-
ciates, Milford, Massachusetts. 
Linear Chart Recorder, Cole Parmer Instrument Co., Chi-
cago, Illinois. 
Integrator Model HP 3392A, Hewlett Packard Co., Avon-
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dale, Pennsylvania. 
Diode Array Spectrophotometer Model 8451A Hewlett Pac-
kard Co. 
pH - Meter, Model 811, Orion Research Inc., Cambridge, 
Massachusetts. 
Gold Fluorescent Lamp Mopdel F40GO, General Electric. 
Tablet Press Single Punch, Stokes. 
Friability Tester, Erweka GmbH, Germany. 
Water Bath, Precision Company. 
Ultraviolet - Visible Spectrophotometer Model Hitachi 
200, Perkin Elmer . 
Laboratory Mill, Arthur H. Thomas Co., Philadelphia, 
Pennsylvania. 
Rotavapor Rotary Evaporator, Buchi. 
Granule Mixer, Turbula, Switzerland. 
3. PROCEDURES 
Nifedipine is quite light - sensitive and degrades 
rapidly on exposure to daylight, tungsten - bulb light, or 
standard fluorescent light. It is however, stable when 
"gold" fluorescent light is used (37). Therefore all proce-
dures described here were carried out in a laboratory area 
which was either dark or had only gold fluorescent lighting. 
3.1. ASSAY DEVELOPMENT 
For quantitative analysis of nifedipine an ultraviolet 
(UV) spectrophotometer was used in conjunction with a rever-
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sed phase high performance liquid chromatography system 
(HPLC). First a 10 mg/L solution of nifedipine in methanol 
was prepared and allowed to degrade under normal laboratory 
light for 7 days. After this period a UV spectrum was ob-
tained of the degraded sample (190 - 400 nm). Next a UV 
spectrum of a fresh solution of nifedipine of the same 
concentration was superimposed on the first spectrum 
(fig.2). From the resulting scans it was evident that the 
difference in the absorbance values of nifedipine and its 
photodegradation product was greatest at 238 nm with the 
absorbance of nifedipine being much greater. A standard 
curve of nifedipine was obtained at this wavelength for 
concentrations between O and 20 mg/L. 
Although several authors have used a UV assay at 238 nm 
for nifedipine (53,54), it is not stability indicating. For 
this reason an HPLC assay was developed using a 3 - 9 mm 
(id) x 30 cm mu-Bondapak C18 (reversed phase) column and a 
variable wavelength detector (Lambda max 480) set at 238 nm. 
A number of mobile phase systems were tested and the one 
which provided the best resolution between the peaks of 
nifedipine and its photodegradation compound was chosen for 
the assay. This consisted of 49 percent methanol in fresh 
distilled, deionized water. The chromatographic conditions 
were as follows: 
The flow rate was 1.2 ml/min., the detector sensitivity 
was 0.05 AUFS and the injection volume (using WISP) was 100 
microliters. 
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Fig. 2. UV absorption spectrum of nifedipine (~) and its photodecomposition product (..._...), 
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A plot was obtained between peak height / area versus 
concentration using standard solutions of nifedipine and was 
used to determine the concentrations of the dissolution 
samples. 
Alternatively, concentrations of dissolution samples 
were obtained by the spectrophotometric method and stability 
was checked by the HPLC method. 
3.2. PHOTODEGRADATION STUDIES 
To study the rate of degradation of nifedipine solution 
in normal laboratory conditions a preliminary study was 
conducted in a lighted room at night to exclude the variable 
intensity of sunlight. 
20 mg/L of nifedipine solution was prepared in three 
different media to test the effect of pH on the rate of 
photodegradation of nifedipine. The first medium was 49% 
methanol in water (corresponding to the mobile phase of the 
HPLC system); the second and the third media were 49% metha-
nol in 0.01 M phosphate buffer with final pH adjusted to 4.2 
and 7 .8 respectively. 
Four ml of each of the three solutions was taken sepa-
rately in a WISP vial and kept exposed to the light in the 
room. At o, 30, 60 and 180 minutes two samples of 25 micro-
liters each were withdrawn from each solution and injected 
into the HPLC system manually. A set of standard solutions 
were also injected during the assay to obtain a standard 
curve at the same conditions. From a peak height analysis of 
the chromatograms the percent of nifedipine remaining in the 
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solution was calculated. 
3.3. SOLUBILITY STUDIES 
The solubility of nifedipine in various media was de-
termined in an attempt to obtain a suitable medium for 
dissolution studies. The apparatus used was similar to the 
dissolution apparatus used in the rotating bottle method 
(38). The media selected were distilled water, hydrochloric 
acid 0.1 N and 1.0 N, sodium hydroxide 0.1 N, and phosphate 
buffer O.OlM (pH 7.4). The temperature of the water bath 
was maintained at 25 ±. 1 degrees Celcius. Glass tubes with 
screw caps were used for holding the soutions. Each tube was 
filled with 20 ml of of the medium and about 10 mg of 
nifedipine thereby ensuring the excess of the drug in the 
tube. Three tubes were used for each media. 
The caps were screwed on the tubes and were wrapped 
securely with a strip of paraf ilm to prevent any leakage. 
The tubes were fixed to the shaft and allowed to rotate in 
the water bath. At 3.5 and 4.5 hours, the tubes were removed 
and 3 ml samples were withdrawn from each tube using a pipet 
fitted with plastic tube containing glass wool to prevent 
solid particles from entering the pipet. The samples were 
assayed immediately by UV spectrophotometer at 238 nm. Simi-
larly the solubility of the coprecipitates were determined 
at 25 degrees. 
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3.4. PREPARATION OF NIFEDIPINE - POLYMER COPRECIPITATE 
Fifty grams of nifedipine powder (crystalline) was 
taken in a 2L round - bottom flask. To this about 400 ml of 
ethanol was added with continuous stirring. Two hundred 
grams of the polymer (PEG 8000 or PVP 40T) was then added 
with stirring and the solution warmed in a water bath at 
about 45 degees Celcius. Stirring was continued until a 
clear solution was obtained. 
The solution was allowed to cool to room temperature 
and the solvent was evaporated under vacuum using a rotary 
evaporator at 40 degrees Celcius. The semi- dried mass was 
crushed and collected in a lL beaker, covered with aluminum 
foil (with holes punched at the top to allow drying) and 
kept in a vacuum oven at room temperature for 48 hours. At 
the end of this period the beaker containing the coprecipi-
tate was removed from the oven and kept in a dessicator for 
further use. 
3.5. TABLETTING 
For preparing tablets the nifedipine - polymer copreci-
pitates were milled separately in a laboratory mill using a 
#20 screen. The two coprecipitates were then mixed in the 
desired ratio, according to the formulation (see table I), 
and 20 grams of the resulting mixture taken in the mixing 
jar. To this, 700 mg (i.e. 3.5%) of Ac-di-sol (disintegrant) 
and 200 mg (i.e. 1.0%) of Cab-0-Sil (antiadherent) was added 
and mixed together in a turbula mixer for fifteen minutes. 
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( TABLE I. Composition of controlled release tablets of 
nifedipine. 
Tablet Amount of ingredient per tablet (mg) 
code PEGa PVPb Ac-di-sol Accurel SLSc Cabosil 
Tl 
T2 
T3 
T4 
T5 
T6 
100 
50 
25 
5 
25 
25 
0 
50 
75 
95 
75 
75 
3.5 
3.5 
3.5 
3.5 
3.5 
3.5 
0 
0 
0 
0 
5 
7.5 
1.5 
1.5 
1.5 
1.5 
1. 5 
1.5 
1 
1 
1 
1 
1 
1 
aPolyethylene glycol 8000 and nifedipine (4:1) coppt. 
bPolyvinylpyrrolidone (40T) and nifedipine (4:1) coppt. 
csodium lauryl sulfate. 
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At the end of this time, the jar was taken out and 300 
mg (i.e. 1.5%) of sodium lauryl sulfate (soluble lubricant) 
was added. The whole contents were then mixed for another 
five minutes. 
For tablets T5 and T6 (see table I), Accurel (1.0 gm 
and 1.5 gm respectively) was added along with Ac-di-sol and 
Cab-O-Sil to the coprecipitate mixture. The rest of the 
procedure was the same as described. 
Tabletting was done using a single - punch tablet press 
operated maunually. The humidity of the room was kept below 
40 percent with a dehumidifier. The lower punch of the 
machine was adjusted according to the theoretical weight of 
the tablet (106 mg for Tl - T4, 111 mg for T5, and 113.5 mg 
for T6). For each formulation about 120 tablets were ob-
tained. The physical properties of the tablets were studied 
and the tablets stored in opaque plastic bottles in a dessi-
cator for dissolution studies. 
3.6. EVALUATION OF TABLET PROPERTIES 
3.6.1 PHYSICAL PROPERTIES: 
Weight variation and disintegration time was studied 
for each type of tablet in accordance with the official 
method (USP XXI). Hardness was tested on five tablets of 
each type using Erweka hardness tester. Friability was dete-
rmined using 10 tablets with Erweka Friability tester at 25 
rpm for 4 minutes for each test. 
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6.2 DISSOLUTION STUDIES: 
Dissolution rate was studied for each kind of tablet 
under two different conditions as described below. In each 
case the dissolution flasks were filled with 1 L of freshly 
prepared distilled water and warmed to 37 ± 1 degrees Cel-
cius. The USP paddle method was used with the stirring speed 
maintained at 150 rpm. All samples were run three times. 
In the first case one whole tablet (containing 20 mg 
equivalent of nifedipine) was taken in each of three flasks 
and the procedure was carried out for all six types of 
tablets Tl through T6. At appropriate intervals, a 3 ml 
sample was withdrawn by means of a pipette fitted with a 
small piece of glass wool to filter off any drug particle. 
The sample volume taken was replaced by an equivalent volume 
(3ml) of fresh distilled water at the same temperature. The 
sample was suitably diluted with warm distilled water and 
assayed using UV spectrophotometer at 238 nm as well as HPLC 
assay as described before. For comparison of the dissolution 
profile of the tablets prepared from the coprecipitates a 
similar procedure was carried out using pure nifedipine 
powder (20 mg) and also commercially available soft - gela-
tin capsules of nifedipine (2 capsules per flask - equiva-
lent of 20 mg nifedipine). 
In the second case the tablets were cut into small 
pieces. A small piece (containing approximately 4 mg equiva-
lent of nifedipine) was weighed accurately and taken in 1 L 
of dissolution media (to approximate sink conditions) and 
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( the above procedure was repeated. From the weight of the tablet fraction the amount of nif edipine was calculated to 
give the dissolution rate expressed as a percent of the 
amount dissolved in a given time interval. 
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( IV. RESULTS AND DISCUSSION 
This section contains an evaluation of the experimental 
protocol and assay techniques used in this study and results 
thus obtained. It also contains a critical discussion of the 
significance and an interpretation of the results. 
For ease of reference the results and discussion are 
organised into the following sections: 
A. Evaluation of the assay methods. 
B. Kinetics of Photodegradation of nif edipine. 
C. Solubility studies. 
D. Evaluation of the physical characteristics of 
tablets. 
E. Disssolution studies. 
A. EVALUATION OF THE ASSAY METHODS 
1. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Table II summarizes the results obtained from the va-
rious mobile phases and flow rates used in developing a 
stability indicating assay HPLC assay for nifedipine. 
The retention times for nifedipine and its photodecom-
posi tion product are denoted by Tr2 and Trl respectively. 
The resolution R was calculated using the formula 
R = 2 (Tr2 - Trl)/ (Wl + W2) (7) 
where Wl and W2 are the base peak width of the degradation 
product and nifedipine respectively. 
From the table it is evident that using 49% methanol in 
water as mobile phase gives the best resolution. Hence this 
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( Table II. Resolution obtained from the various mobile phase 
systems. 
Mobile Phase Ratio Flow Trla Tr2b RC 
(ml/min) (min) (min) 
methanol/water 60:40 1.1 5.4 6.0 <0.5 
-do- 55:45 1.4 5.6 6.6 0.5 
-do- 50:50 1. 0 10.1 12.8 0.96 
-do- 49:51 1.4 11.1 14.9 1.15 
-do- 48:52 1.5 10.4 14.0 1. 09 
-do- 45:55 1.5 12.0 15.8 0.95 
methanol/acetate 48:52 1.4 7.8 9.8 0.71 
-buf.(0.05M,pH4.0) 
-do- 45:55 1.4 10.4 13.8 1. 07 
methanol/acetate 50:50 1. 4 8.0 10.0 0.92 
-buf. (0.05M,pH6.0) 
methanol/phosphate 62:48 1. 0 5.3 6.0 <0.5 
-buf.(O.OlM,pH4.7) 
acetonit/acetate 5:7 1.2 7.6 7.6 0 
-buf. (0.05M,pH4.0) 
-do- 1:2 1. 5 12.4 12.4 0 
aTrl is the retention time of the photodegradation product. 
bTr2 is the retention time of nifedipine. 
CR is the resolution given by the equation 
R = 2 (Tr2 - Trl) I (Wl + W2) (see text) . 
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was selected for the assay of nifedipine. A typical chroma-
togram is shown in figure 3. 
A linear relationship was found to exist between peak 
height (as well as peak area) and nifedpine concentration. 
Figures 4 and 5 show that this linearity was held in the 
concentration range O - 10 mg/L. However, the relationship 
between peak area (or peak height) and concentration varied 
everytime a fresh mobile phase was used. To overcome this 
problem a standard curve was generated during each run and 
the sample concentrations were determined from the correspo-
nding relationship between peak area or height and concen-
tration of the standard solutions. 
Another problem with the HPLC assay was that it was 
very slow. For this reason it was used in conjunction with 
the UV assay described below. 
2. ULTRAVIOLET SPECTROPHOTOMETRIC METHOD 
The use of UV spectrophotometer at a wavelength of 238 
nm provided a simple, relible and sensitive assay which was 
also rapid and reproducible. Detection was linear in the 
range of concentrations tested (O - 20 mg/L). The absorbance 
(A) was related to the concentration (C) by the equation 
(see fig. 6): 
A = 0.0607C + 0.007 (8) 
The coefficient of correlation r = 0.9998 
To check for degradation of nif edipine during disso-
1 u ti on or solubility studies, one of the three samples for 
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Fig. 5. HPLC calibration curves using peak areas. 
SD. 0 
45.0 
40. 0 
~.o 
< 
w 30.0 
0::: 
< 
... 
:::s::: 25. 0 l.O 
< 
w 0.... 20.0 
15. 0 
10. 0 
5. 0 
o. n 
0. 0 2.0 4. 0 6.D 8. D 10. D 
CONCENTRATION (MG/L) 
( 
( 
E 
i:: 
co 
CV) 
N 
Q) 
i:: 
•r-
0.. 
•r-
-a 
Q) 
4-
•r-
i:: 
~ 
0 
4-
Q) 
> 
~ 
~ 
u 
i:: 
0 
+-' 
r(j 
~ 
_Q 
.--
r(j 
u 
> 
:::> 
. 
l.O 
en 
LL 
0 
0 
~ 
0 
0 
0 
0 
0 
Ill 
ci 
38NV8tJOS8V 
50 
0 
0 
0 
0 
tO 
N 
C(J 
,-..,, 
E 
'-.... 
CJ) 
:J 
..._.,,, 
z 
0 
~ 
er: 
l-
z 
w 
u 
z 
0 
u 
( 
each time point in each batch was also assayed by the HPLC 
method. The results obtained from the two methods for one 
study were compared (see under dissolution studies in this 
section) and it was found that the difference in the concen-
trations obtained from the two methods is very small. 
B. KINETICS OF PHOTODEGRADATION OF NIFEDIPINE 
The results of a preliminary study of the kinetics of 
photodegradation of nifedipine are presented in table III. 
On plotting the results on a log - linear scale (fig. 7), it 
is seen that the photodegradation follows first order kine-
tics. The t 90 of degradation was found to be about 19 mi-
nutes in a normally lighted room during the night. 
Thoma and Klimek (102) studied the degradation kinetics 
of nifedipine in daylight. They reported a t 90 of about 7 
minutes in winter and about 1 minute in the summer. The 
purpose of our investigations was to see if, by excluding 
daylight from the room, the degradation of nifedipine could 
be prevented for a sufficient length of time to perform 
dissolution or solubility experiments. From the results it 
is clear that even in the absence of daylight nifedipine 
solutions are extremely photosensitive to normal laboratory 
light. 
Another objective of this preliminary study was to see 
if there is a measurable difference in the rate of degrada-
tion of nifedipine when the pH of its solution was acidic or 
alkaline. 
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Table III. Photodegradation of nifedipine. 
Time (min) % nifedipine remaining in solutiona 
0 
30 
60 
120 
asolution of 20 mg/L 
A. 49% methanol in 
B. 49% methanol in 
c. 49% methanol in 
A 
100 
84.0 
74.2 
50.2 
B 
100 
84.1 
75.1 
c 
100 
83.9 
74. 7 
prepared in the following solvent: 
water. 
phosphate buff er (final pH 4.2). 
phosphate buff er (final pH 7.8). 
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Fig. 7. Rate of photodecomposition of nifedipine showing First order decay. 
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From the results obtained (Table III) it is clear that 
in the pH range of 4.2 - 7.8 there was no appreciable diffe-
rence in the rate of degradation. 
When solutions of nifedipine were made in methanol and 
kept in colored glassware in a refrigerator there was no 
detectable degradation for at least one week. 
C. SOLUBILITY STUDIES 
The results of the solubility studies are shown in 
table IV. It is clear that the solubility of nifedipine in 
water at 25 degrees Celcius is extremely low (about 5 mg/L). 
Further the solubility is not affected significantly (P > 
0.05) in the pH range of 1 to 7.4. These results are in 
accordance with the results obtained by Boje et al (10) who 
reported a solubility of 5 - 6 micrograms per ml over pH 2.2 
- 10.0 at 25 degrees. 
With lN hydrochoric acid or O.lN sodium hydroxide as 
the solvent the absorbance values were highly unstable. 
Hence solubility determinations could not be made with these 
solvents. 
The solubilities of the two coprecipitates were higher 
than the solubility of nifedipine. Especially the coprecipi-
tate containing polyvinyl pyrrolidone (40T) as the polymer 
exhibited a four - fold increase in solubility over nifedi-
pine. 
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Tab1e IV. Solubility of nifedipine and its coprecipitates 
at 25 degrees Celcius. 
Physical Form Solvent Absorbancea 
(238 
crystalline water 0.304 
-do- phos . ( 7 • 4) b 0.259 
-do- O.lN HCl 0.359 
-do- l.ON HCl 
-do- O.lN NaOH 
peg coppt water 0.535 
pvp coppt water 1. 364 
amean ± standard deviation (n = 3). 
bPhosphate buffer (O.OlM) pH 7 .4. 
nm) 
+ 0.027 
-
+ 0.026 
-
+ 0.047 
-
c 
--
c 
+ 0.024 
-
+ 0.036 
-
Solubilitya 
(mg/l) 
5.01 + 0.44 
-
4.26 + 0.43 
-
5.91 + 0.77 
-
c 
--
c 
--
8.82 + 0.39 
22.47 + 1. 54 
-
ccould not be determined because of rapid change in absorba-
nee. 
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D. EVALUATION OF THE PHYSICAL CHARACTERISTICS OF THE TABLETS 
The physical characteristics of tablets can affect the 
release rate of drug. Also parameters such as weight varia-
tion and friability must lie within an acceptable limit for 
the tablets to be acceptable. Therefore it was necessary to 
evaluate the physical characteristics of each batch of tab-
lets Tl through T6. Table V shows the results obtained from 
these studies. 
All the batches pass the official weight variation test 
as described (USP XXI) for this weight category (+10% varia-
tion is acceptable for tablets weighing 130 mg or less). 
Similarly, the friability was extremely low for each 
batch of tablets although hardness was low for batches T3 
and T4. In general, the maximum hardness imparted to the 
tablets decreased with increasing proportion of PVP copreci-
pitate. With 100 mg PVP per tablet the tablets produced were 
too soft to withstand any sort of handling and were there-
fore not taken for study. 
On adding Accurel the hardness of T3 tablets increasd 
as expected. With 5 and 7.5 mg Accurel per tablet (T5 and T6 
respectively) added in the formulation of T3 tablets the 
hardness increasd significantly (P < 0.01). However the 
difference between the hardness in tablets of batches T5 and 
T6 was not significant. 
Addition of Accurel also prolonged the disintegration 
time of T3 tablets significantly (P < 0.01) and here again 
the difference between T5 and T6 tablets was not signif i-
cant. 
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Tab1e V. Physical characteristics of tablets. 
PARAMETER 
wt. Var. Friability Disint. Time 
(mg) (%) 
Tl 100-106 0.1 
T2 107-111 0.1 
T3 104-110 0.0 
T4 106-112 0.0 
TS 106-116 0.0 
T6 112-113 0.0 
aRange of weights, n = 10. 
bFor 10 tablets. 
cMean + Standard Deviation, n = 6. 
dMean + Standard Deviation, n = 5. 
57 
(min) 
6.5+0.5 
12.8+1.8 
11. 7+0. 8 
14. 2+1. 0 
19.3+0.5 
19.3+1.0 
Hardness 
(kg) 
3.6+0.2 
3.6+0.4 
1. 8+0. 2 
1. 6+0 .1 
2.4+0.2 
2.6+0.1 
( 
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E. DISSOLUTION STUDIES 
Tables VI through IX and figure 8 show the results 
obtained from the dissolution studies under non - sink con-
ditions. In these studies 20 mg equivalent of nifedipine 
was taken in 1 liter of water at 37 degrees Celcius. From 
the results it is clear that the dissolution rate of the 
pure drug is extremely low. On the other hand the release 
rate of nifedipine from the commercially available Adalat 
soft - gelatin capsule is extremely high and plateau concen-
trations are reached between 10 and 20 minutes. 
Among the test tablets the dissolution rate increased 
in the order Tl < T2 < T3 < T4, i.e., in the order of 
increasing fraction of PVP coprecipitate. With all of the 
tablets the dissolution rate was much higher than that of 
pure nifedipine powder. In the latter case only about 2 mg 
of the drug dissolved in 2.5 hours. The low dissolution rate 
was expected due to the poor solubility of nifedipine in the 
crystalline form which is about 11.5 mg/L of water at 37 
degrees (96,98). The enhanced release of nifedipine from the 
four tablets is probably due to the presence of nifedipine 
in the amorphous form in the two coprecipitates. Although 
the exact physical nature of these dispersed systems was not 
investigated it is believed that reduction of particle size 
of the drug to the molecular and / or colloidal level is the 
primary contributing factor for this striking phenomenon 
(98) . 
The increase in dissolution rate cannot be ascribed to 
58 
( 
( 
( 
Tab1e VI. Dissolution of Adalat capsulesa. 
Time Peak Areab Concb 
(min) (mg/L) 
10 44.5 + 0.60 17.8 + 0.24 
- -
20 45.9 + 0.50 18.3 + 0.20 
- -
30 46.8 + 0.48 18.7 + 0.19 
- -
45 46.9 + 0.38 18.7 + 0.15 
-
60 47.8 + 0.37 19.1 + 0.15 
- -
90 47.32 + 0.32 18.9 + 0.13 
- -
120 47.35 + 0.20 18.9 + 0.08 
- -
360 47.60 + 0.35 19.0 + 0.14 
- -
aTwo capsules (equivalent to 20 mg of nifedipine) per liter 
of water. The standard curve was plotted using the equa-
tion : 
Y = 4.17X + 0.65 (r = 0.9998) 
The dilution factor for the samples was 5/3. 
bMean ± standard deviation, n = 3. 
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Tab1e VII. Dissolution of nifedipine powdera. 
Time Peak Heightb Conch 
(min) (cm) (mg/L) 
10 2.5 0.26 
20 4.2 0.44 
30 5.7 0.59 
60 9.1 0.95 
90 12.8 1.33 
120 15.7 1. 63 
150 20.0 2.08 
a2 O mg of powder/ liter of water. Standard curve was drawn 
(dilution factor of samples was 5/3) using the equation: 
Y = 9.629X + 0.586 
bMean of 2 readings. 
(r = 0.9914). 
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Tab1e VIII. Dissolution of tabletsa Tl and T2 under non -
sink conditionsb. 
------- Tl 
------------
------------T2------------
Time Absorbancec Concc Absorbancec Con cc 
(min) (238nm) (mg/L) (238nm) (mg/L) 
10 0.139+0.005 3.82+0.14 0.223+0.009 6.13+0.25 
20 0.185+0.006 5.08+0.16 0.309+0.007 8.48+0.18 
30 0.214+0.004 5.88+0.ll 0.323+0.005 8.86+0.14 
45 0.240+0.003 6.59+0.07 0.340+0.003 9.34+0.07 
60 0.259+0.002 7.12+0.06 0.350+0.009 9.60+0.25 
90 0.283+0.006 ( 7.76+0.16 0.354+0.005 9.72+0.14 
120 0.298+0.004 8.17+0.11 0.366+0.008 10.04+0.22 
180 0.320+0.003 8.78+0.07 0.376+0.007 10.32+0.18 
480 0.358+0.006 9.83+0.16 0.388+0.003 10.66+0.07 
18hr 0.371+0.002 10.18+0.06 0.388+0.003 10.66+0.07 
asee Table I page 40 for composition of tablets. 
bone tablet (equivalent to 20 mg nifedipine) per liter of 
water. 
cMean + Standard Deviation (n = 3) of diluted samples (dilu-
tion factor = 5/3). 
( 
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Table IX. Dissolution of tabletsa T3 and T4 under non - sink 
conditionsb. 
------------ T3 --------- ----------- T4 -----------
Time Absorbancec Concc Absorbancec Concc 
(min) (238nm) (mg/L) (238nm) (mg/L) 
10 0.256+0.007 7.03+0.18 0.275+0.007 7.54+0.18 
20 0.378+0.002 10.39+0.0 0.396+0.007 10.87+0.18 
30 0.384+0.004 10.55+0.11 0.438+0.008 12.03+0.21 
45 0.390+0.006 10.70+0.16 0.441+0.008 12.10+0.21 
60 0.397+0.006 10.91+0.16 0.445+0.005 12.21+0.14 
90 0.392+0.002 10.75+0.06 0.443+0.005 12.17+0.14 
120 0.398+0.003 10.93+0.07 0.442+0.001 12.14+0.03 
180 0.398+0.002 10.93+0.06 0.440+0.002 12.09+0.06 
480 0.414+0.005 11. 37+0 .14 0.443+0.005 12.17+0.14 
aFor composition of tablets T3 and T4 see table I page 40. 
bone tablet (equivalent to 20 mg of nifedipine) per liter of 
water. 
cMean + Standard deviation (n = 3) of diluted samples (dilu-
tion factor = 5/3). 
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Fig. 8. Dissolution profiles of formulations under non - sink conditions. 
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increase in the solubility of nifedipine since the solubili-
ty at 37 degrees was not measured. Although an increase was 
found in the solubility of nifedipine in the coprecipitate 
systems at 25 degrees other authors have reported only a 
slight increase of the drug in aqueous solutions of PVP 
(96,98) at 37 degrees. Since the saturation concentrations 
achieved from the tablets (fig. 8) are in the range of the 
reported solubility of nifedipine (about 11 mg/L) in water 
at 37 degrees this argument is convincing. 
A higher dissolution rate with higher PVP fraction can 
be explained by the observations of Sumnu (98) who found 
that in solid disperse systems of nifedipine in PVP (in the 
ratios 1:3 and 1:9) the drug stayed essentially in the 
amorphous state with no signs of crystallinity. On the other 
hand nifedipine - PEG coprecipitates, in the same ratios of 
drug and polymer, indicated presence of crystallinity. 
Other factors that could account for this phenomemon 
are reduced surface tension on the drug particles (73), 
formation of soluble complexes with the polymer (33,34), and 
its dispersion form (11). 
Previous studies on the dissolution behaviour of nife-
dipine coprecipitates have found that in these systems the 
concentration of nifedipine in the solution increases rapid-
ly in the beginning, forming a supersaturated solution, and 
then decreases after half an hour due to crystallization of 
the drug (96,98). We did not observe any decrease in concen-
trations possibly due to the smaller amount of drug taken 
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per liter of the dissolution medium. In the reported studies 
50 mg equivalent of nifedipine was taken in 500 ml of the 
medium while we used only 20 mg equivalent of the drug in lL 
of water. 
Tables X through XIII compare the results of dissolu-
tion of the tablets obtained from the UV and HPLC assays. 
The HPLC assay was performed on one sample per time point in 
the dissolution profile of each tablet. Therefore the con-
centrations obtained from the HPLC are compared with the 
corresponding concentrations obtained with the UV assay for 
each case. For this reason the concentrations in column 3 in 
the tables X through XIII are slightly different from the 
concentrations in column 3 and 5 in tables VIII and IX which 
are the means of 3 samples. 
The difference in the results obtained by the two assay 
methods is negligible - about 2% for the four taken toget-
her. Since the UV assay was less cumbersome, more reproduci-
ble and much faster it was used for further dissolution 
studies. 
Tables XIV and XV and figure 9 show the dissolution 
profiles of all the six tablets in "near sink" conditions. 
Sink conditions are approximated when the volume of the 
dissolution medium is five to ten times the saturation 
volume of the medium (38). Since in our studies a fraction 
of the tablet equivalent to about 4 mg of nifedipine was 
taken, and since the solubility of nifedipine has been 
reported to be about 11 to 12 mg/L at 37 degrees (also seen 
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Table X. Comparison of UV and HPLC assay results for 
dissolution of tablet Tl. 
Time Absorb Cone Peak Areaa Cone Differ 
(min) (238 nm) (mg/L) (mg/L) (%) 
10 0.148H4 3.95 9.08 3.80 3.70 
20 0.188 5.16 13.01 5.45 - 5.61 
30 0.218 5.98 14.54 6.09 - 1.84 
45 0.243 6.67 16.30 6.83 - 2.36 
60 0.261 7.17 17.33 7.26 - 1. 24 
90 0.280 7.69 18.85 7.89 - 2.67 
( 120 0.301 8.26 19.71 8.26 0.00 
180 0.320 8.79 20.84 8.73 0.69 
480 0.357 9.80 23.32 9.77 0.33 
18 hr 0.369 10.13 23.91 10.02 1. 09 
-----------------------------------------------------------
Mean - o. 78 
-----------------------------------------------------------
aThe standard curve was drawn using the equation: 
Y = 3.979 X + 0.207 (r = 0.9999) 
Dilution factor of samples = 5/3. 
( 
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Table XI. Comparison of UV and HPLC assay results for disso-
lution of tablet T2. 
Time Absorb Cone Peak Areaa Cone Differ 
(min) (238 nm) (mg/L) (mg/L) (%) 
10 0. 218 5. 9 8 13. 5 3 5.67 5. 2 3 
20 0.302 8.29 19.39 8.12 2.03 
30 0.318 8.73 20.84 8.73 0.00 
45 0.337 9.25 21.91 9.18 0.76 
60 0.360 9.88 23.26 9.74 1. 39 
90 0.356 9.77 23.27 9.75 0.24 
120 0.370 10.16 23.71 9.93 2.25 
180 0.377 10.35 24.38 10.21 1.33 
480 0.390 10.71 24.67 10.33 3.52 
18 hr 0.394 10.82 24.76 10.37 4.15 
-----------------------------------------------------------
Mean 2.09 
-----------------------------------------------------------
astandard curve same as for Tl 
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Table XII. Comparison of UV and HPLC assay results for 
dissolution of tablet T3. 
Time Absorb Cone Peak Areaa Cone Differ 
(min) (238 nm) (mg/L) (mg/L) (%) 
10 0.251 6.89 16.28 6.47 6.09 
20 0.380 10.43 24.39 9.70 6.99 
30 0.384 10.55 25.98 10.33 2.08 
45 0.391 10.73 26.60 10.58 1.40 
60 0.390 10.71 25.94 10.32 3.64 
90 0.390 10.71 26.36 10.48 2.15 
120 0.401 11. 01 26.97 10.73 2.54 
( 180 0.400 10.98 27.12 10.79 1. 73 
480 0.415 11. 39 27.85 11. 08 2.72 
------------------------------------------------------------
Mean 3.26 
------------------------------------------------------------
astandard curve was drawn using the equation 
y = 4.191 x + 0.044 (r = 0.9999) 
Dilution factor of samples = 5/3. 
( 
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Table XIII. Comparison of UV and HPLC assay results for 
dissolution of tablet T4. 
Time Absorb Cone Peak Areaa Cone Dif f er 
(min) (238 nm) (mg/L) (mg/L) (%) 
10 0.271 7.44 17.24 6.85 7.94 
20 0.389 10.68 25.62 10.19 4.59 
30 0.430 11.86 28.76 11. 44 3.55 
45 0.432 11.86 29.30 11. 65 1. 77 
60 0.440 12.09 29.26 11. 64 3.72 
90 0.438 12.03 29.47 11. 72 2.58 
120 0.441 12.10 30.06 11. 95 1. 24 
180 0.438 12.03 30.11 11. 97 0.50 
480 0.442 12.14 29.53 11. 74 3.29 
-----------------------------------------------------------
Mean 3.24 
-----------------------------------------------------------
astandard curve same as for T3. 
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Table XIV. Dissolution of tablets Tl, T2 and T4 in "near 
sink" conditions. 
Time Percent released 
(min) 
Tl T2 T4 
10 25.2 + 4.3 43. 7 + 0.9 65.2 + 0.4 
- -
20 31.5 + 0.2 55.2 + 1. 7 7 4. 6 + 1.4 
-
30 3 6. 7 + 0.8 62 .4 + 2.8 8 0.1 + 5.3 
- -
45 4 7 .8 + 1.5 68.2 + 2.5 83.4 + 2.7 
-
60 48. 9 + 1.5 74.6 + 3.6 85. 0 + 3.7 
- -
90 55. 6 + 1.3 77.1 + 0.9 89. 6 + 6.5 
- -
120 61.2 + 1.0 77 .5 + 0.8 92. 7 + 4.4 
- -
-
( 180 67.6 + 1.0 83.0 + 2.5 
400 96.4 + 8.1 
540 92.6 + 1.4 101.0 + 3.3 
- -
Tab wta 4.07 4.01 4.05 
aweight (in mg) of fraction of tablet (equivalent of nifedi-
pine) taken in 1 liter of water. 
( 
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Tabl.e RXV. Dissolution of tablets T3, TS, and T6 in "near 
sink" condition. 
Time Percent released 
(min) 
T3 TS T6 
10 6S. 6 + 0.9 S3 .4 + 1.2 4 3.8 + o.s 
-
20 7 3. 6 + 3.S 6S.O + 3.0 S2. 2 + 1.S 
- - -
30 7 6.S + 3.9 66.9 + 0.8 60. 2 + 1.8 
4S 82. 3 + 2.7 74.8 + o.s 67 .4 + 1.1 
- -
60 82.4 + 1.1 78.S + 0.6 7 2.4 + 0.8 
-
-
90 87. 6 + 1.1 8S.1 + 2.S 77 .8 + 2.6 
- -
120 87. 7 + 1.8 88. 0 + 1.S 8S. s + 2.2 
- - -
( 180 92. 7 + 1.S 87.6 + 3.1 - -
400 91.7 + 0.7 
460 98.4 + 1.9 94. 7 + 3.S 
-
Tab w_ta 4.03 3.83 3.67 
aweight (in mg) of fraction of tablet (equivalent of nifedi-
pine) taken in 1 liter of water. 
( 
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from figure 8), the volume of 1 liter of water taken in our 
studies was about 3 times the saturation volume. Hence it is 
appropriate to say that sink conditions were -nearly achieved 
in these studies. 
From fig. 9 it can be seen that the dissolution rates 
of tablets not containing Accurel polymer increase in the 
order Tl < T2 < T3 = T4. The dissolution rates of tablets T3 
(containing 25% PEG coprecipitate and 75% PVP coprecipitate) 
and T4 (containing 5% PEG coprecipitate and 95% PVP copreci-
pi tate) were not significantly different (P > 0.05) for 10, 
20 and 30 minutes. For both of these tablets about 75% of 
the drug was released in the first 20 minutes. It was then 
decided to formulate a tablet which would release about 50% 
of the drug in 20 minutes but no more than 90% in 3 hours. 
For this we chose to modify the formulation of T3 using 
Accurel polymer. our hypothesis was that addition of a small 
amount of this hydrophobic polymer would reduce the dissolu-
tion rate and bring it to the desired level. 
In the first case (tablet TS) 5 mg of Accurel was added 
per tablet (total weight per tablet was 111 mg). As expected 
the dissolution rate decreased but still about 65% of the 
drug was released in 20 minutes and 93% was released in 3 
hours. 
In the second case (tablet T6) 7.5 mg of Accurel was 
added per tablet and for this tablet about 52% of the drug 
was released in 20 minutes and about 88% in 3 hours. Since 
the dose of commercially available nifedipine capsules is 10 
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( to 20 mg tablet T6 would provide a suitable dosage regimen 
if the in vivo release is similar to the in vitro results 
obtained from our studies. 
The convenience with which the release can be modified 
from these tablets are encouraging although a zero order 
release was not seen at the small fraction of the polymer 
matrix. Further studies are needed with other proportions of 
PEG or PVP and nifedipine and with formation of bilayer 
tablets which would produce slower release from one half and 
quicker release from the other. In this way a higher concen-
tration of Accurel or other rate controlling matrix substan-
ce can be used which may give a better control of release 
approaching zero - order. 
Also, in vivo studies need to be done in order to 
better understand the relationship between the in vitr~ 
release and bioavailability. 
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V. CONCIDSIONS 
1. The UV spectrophotometer at 238 nm was a sensitive, 
reproducible and reliable assay method for the quantifica-
tion of nifedipine for the dissolution studies. Stability 
can be checked by the HPLC method which is also useful for 
the decomposition studies. 
2. The photodegradation of nifedipine in solutions follows 
first order kinetics with a t 90 of about 19 minutes in a 
normally lighted room in the absence of daylight. 
3. In the pH range of 4.2 - 7.8 there is no appreciable 
difference in the rate of photodegradation of nifedipine. 
However, solutions kept in colored glassware and stored in a 
refrigerator are quite stable for at least one week. 
4. The solubility of nifedipine in water is about 5 mg/L at 
25 degrees Celcius. The solubility in phosphate buffer (pH 
7.4) and 0.1 N HCl was not significantly different from 
that in water. 
5. The tablets prepared with the various formulations had 
acceptable weight variation and friability. However tablets 
prepared with a high PVP fraction had low hardness. 
6. Addition of 5% and 7.5% of Accurel increased the hardness 
and disintegration time. 
7. The dissolution rate of tablets increased in the order of 
increasing fraction of PVP coprecipitate. Hence PVP is a 
better material than PEG for the enhancement of dissolution 
rate of nifedipine. 
75 
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8. Accurel effectively retards the release of nifedipine 
from the homogeneously dispersed monolithic tablet. However 
the release rates at low Accurel concentrations do not 
exhibit zero - order or the square root of time pattern. 
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